AVALON GLOBOCARE CORP.

Investor Presentation

April 2017

OTCQB: AVCO

Disclaimer

Statements pertaining to future financial and/or operating results, future growth in research,technology, clinical development, and potential opportunities for Avalon GloboCare Corp. and itssubsidiaries, along with other statements about the future expectations, beliefs, goals, plans, orprospects expressed by management constitute forward-looking statements. Any statements that arenot historical fact (including, but not limited to statements that contain words such as “will,” “believes,”“plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-lookingstatements, which involve risks and uncertainties, including, without limitation, risks inherent in thedevelopment and/or commercialization of potential products, uncertainty in the results of clinical trialsor regulatory approvals, need and ability to obtain future capital, and maintenance of intellectualproperty rights. Actual results may differ materially from the results anticipated in these forward-looking statements an as such should be evaluated together with the many uncertainties that affect thebusiness of Avalon GloboCare or its subsidiaries, particularly those mentioned in the cautionarystatements found in Avalon GloboCare’s Securities and Exchange Commission filings. Avalon GloboCaredisclaims any intent or obligation to update these forward-looking statements. (STEVE FLEMING TOUPDATE)

Mission and Vision

Avalon GloboCare Corp. (OTCQB: AVCO) is a premiere healthcaremanagement provider and biotechnology developer, dedicated tointegrating and managing global healthcare resources, empoweringhigh-impact biomedical innovation and technologies, as well asengaging in bio-venture investment.

• Diversified healthcare technology company • Highly experienced and well respected management team • Focused on a large growing market opportunity for cell-

based therapeutics/diagnostics, high-impact biomedical innovation, accelerated clinical development, and turn-key commercialization

• Access to capital in order to successfully execute on its business plan and developmental roadmap

Our Values and Investment Highlights

Equity Snapshot

Avalon GloboCare Corp. Exchange OTCQB: AVCO

Recent Stock Price $1.49

Shares Outstanding 62 million shares

Market Capitalization $92 million

Cash (pro forma a/o 3/31/2017) $5,120,000

Float 3,750 shares

Insider Ownership 79.8 %

Fiscal Year-End 12/31/2016

Our Operating Model: “Technology + Service”Avalon GloboCare Corp., headquartered in Freehold NJ, is a global intelligent healthcare technology developer and service provider dedicated to integrating and managing global resources empowering high-impact biomedical innovation:

DeveloperLong Term Growth

Technology Platform

Avalon Cell Exosome Technology (“Liquid Biopsy” & Tx) Endothelial / Vascular Technology CD8+ “Killer T-Cell” Immuno-Oncology

Service ProviderImmediate Cash Flow

Avalon Rehabilitation• M & A Targets

Healthcare Facility • Global Headquarters -- Avalon

Executive Building, Freehold, NJ• CAP certified Laboratory

Management Team

Daniel Lu Chairman, Co-founder; currently Chairman of the DaoPei Medical Group (DPMG) comprising top hospitals, stem cell banks and clinical labs in China.

David Jin M.D., Ph.D. , Chief Executive Officer, President, Co-founder; former faculty at Ansary Stem Cell Institute at Weill Cornell Medical College of Cornell University; former Chief Medical Officer of BioTime Inc. (NYSE: BTX) and subsidiary OncoCyte Corportion (NYSE: OCX)

Luisa Ingargiola Chief Financial Officer, former CFO, Secretary and Director of MagneGas (NASDAQ: MGNA) . Between 1992 and May 2007, served in a variety of capacities at MetLife Insurance Company. Master Degree in Health Administration.

Meng Li Chief Operating Officer, Ms. Li has 15 years of executive experience in international marketing, branding, communication, and media investment consultancy. Ms. Li served as Managing Director at Maxus/GroupM (a WPP Group company) responsible for business P&L and corporate management from 2006 to 2015.

Steven Sukel, J.D. Senior Vice President of Healthcare Property Management

Hebei Yanda Lu Daopei HospitalBeijing Lu Daopei HospitalBeijing Lu Daopei Hematology HospitalShanghai Daopei HospitalHubei Provincial Stem Cell Bank, Wuhan BiolakeDaopei Special Hematolgy LaboratoriesLizhuang Tongji Hospital, Lu Daopei Hematology-Oncology CenterChang An Hospital, Lu Daopei Hematology-Oncology CenterDaopei Hematology Institute>100 affiliated network hospitals in China

Corporate Foundation – Clinical Bases in China

DaoPei Medical Group (DPMG):

Professor Daopei Lu is well acclaimed as China’s “Father of Hematopoietic Stem Cell Transplant”

Prof. Daopei Lu

Hebei Yanda Lu Daopei Hospital is top-ranked private Hospital in China

AVCO established our flagship clinical bases for exosome technology, endothelial biobanking, integrated rehabilitation, and bio-informatics (“Big Data”) at DPMG and will expand throughout China

Corporate Foundation -- Partnerships JV – GenExosome Technology

exosome-based diagnostic and therapeutic programs

JV -- Beijing Doing Biotechnology (Beijing)cell-based immunotherapy (DC, CIK, CAR-T, CAR-NK), anti-aging

SRA -- Cornell University, Memorial Sloan-Kettering Cancer Centerendothelial cell bio-banking, processing and therapeutics;exosome technology and clinical studies

Partnership -- Kessler Rehabilitation Institute, FOX Rehabilitaion (in negotiation)Integrated Rehab Programs

JV -- Heat Biologics (NASDAQ: HTBX; in negotiation)

Technology Platform (“Avalon Cell”)

AVCO believes the future of medicine will evolve toward cell-based therapeutics and diagnostics. Avalon Cell is focused on cell-based therapies and technologies with emphasis in the field of in vitro diagnostics, regenerative medicine and cancer immunotherapy. AVCO leverages the expertise of Daopei Medical Group and the strong technical background of our management team, to advance cell technologies globally.

COMPANY FOCUSIdentify disruptive and high-impact bio-tech opportunities in the U.S.A. and China,

and fast track them to clinical development and commercialization worldwide.

Technology Platform (“Avalon Cell”)

o Exosome are cell derived vesicles that are present in most body fluids such as blood, urine and saliva;

o Exosomes are being developed as diagnostics (“liquid biopsy”) and therapeutics for various diseases;

o AVCO is positioned to become the foremost developer of the exosome technology domain, with focus in the following unmet diagnostic and therapeutic areas:

Early detection of oral cancer (saliva-based)Early detection of ovarian cancer (blood-based)Liver fibrosisDegenerative Disorders (Alzheimer’s disease, arthritis, osteoporosis…etc.)

o Collaborations with Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center

o Joint Venture: “GenExosome Technologies Corp.”, to bring exosome technology, clinical development, and IP into the USA and develop technology globally.

Exosome Technology

Technology Platform (“Avalon Cell”)

o Endothelial cells are inner lining of vasculature throughout our body o Weill Cornell Medical College of Cornell University and Ansary Stem Cell Institute have

been the top endothelial research and technology development:Dr. Ralph Nachman: first in vitro culture of HUVEC; initiated the whole

field of angiogenesisDr. Shahin Rafii: discover of endothelial progenitor cells (EPCs),

involvement of Ecs/EPCs in tissue and organ regenerationDr. David Jin: homing and mobilization of EC/EPC/Hemangiocytes, vascular

niche, cancer targeted therapy based on anti-angiogenesisDr. Yen-Michael Hsu: Standardization and SOP development in EC bio-

banking and clinical-grade processing

Our Focus: Establishing Bio-banking Network of human umbilical vein-derived endothelial cells (HUVEC Bio-banking); EPC/EC therapeutic enhancement programs (in

conjunction with stem cell and anti-cancer therapies)

Endothelial Technology

Technology Platform (“Avalon Cell”)

CD8+ “Killer T-cell” Immuno-Oncology

Technology Platform (“Avalon Cell”)

CD8+ “Killer T-cell” Immuno-Oncology

Service Platform (“Avalon Rehab”)Rehabilitation medicine is a growing trend in China

With expertise in integrating global technologies and resources withphysical medicine and rehab, AVCO will position itself as a leader viaour “Avalon Rehab” platform:

• A turnkey, full suite of rehab services including PT, OT, robotic engineering,cybernectics, and clinical nutrition

• AVCO will also engage in strategic partnerships with our institutional clients inChina, building the leading and most respected network of integrated physicalmedicine and rehabilitation, particularly for cancer patients

Initial Flagship Clinical Locations Strategic PartnersHebei Yanda Lu Daopei Hospital MD Anderson Cancer CenterBeijing Lu Daopei Hospital Mayo ClinicBeijing Lu Daopei Hematology Hospital Kessler Institute for Rehabilitation/FOX

Healthcare Facility Management & Acquisition

Currently includes healthcare property management services, primarily by acquiring and managing healthcare real estate facilities, stem cell banks, and CAP-certified laboratory that will compliment our existing platforms.

Thank You !